Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWI0M8)

• Drug Name: ISOPPADS Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3978952
  TTD Drug ID: DMWI0M8

Molecule-Related Drug Atlas

Drug(s) Targeting P2X purinoceptor 3 (P2RX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefapixant	DM4GWL7	Cough	MD12	Phase 3	[3]
BAY-1902607	DMYSQMW	Cough	MD12	Phase 2	[3]
BAY 1902607	DMFA4CK	Cough	MD12	Phase 1/2	[3]
AF-130	DM8LG2I	Hypertension	BA00-BA04	Phase 1	[4]
BAY-1817080	DMNL5G7	Endometriosis	GA10	Phase 1	[3]
BAY 1817080	DMF9ALP	Cough	MD12	Phase 1	[5]
BzATP	DM37GYA	Discovery agent	N.A.	Investigative	[6]
TNP-ATP	DMVZY0X	Discovery agent	N.A.	Investigative	[7]
LVAYPWT	DMIO405	Discovery agent	N.A.	Investigative	[1]
MK-3901	DM5EQ7F	Pain	MG30-MG3Z	Investigative	[6]

Drug(s) Targeting P2X purinoceptor 7 (P2RX7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CE-224535	DMFCLT6	Arthralgia	ME82	Phase 2/3	[8]
AZD9056	DMJGYPK	Chronic obstructive pulmonary disease	CA22	Phase 2	[9]
LY3857210	DMZO2V2	Pain	MG30-MG3Z	Phase 2	[10]
BIL010t	DMV1EA9	Alzheimer disease	8A20	Phase 1/2	[3]
EVT 401	DMOG8IE	Rheumatoid arthritis	FA20	Phase 1	[11]
SGM-1019	DMDAHEL	Inflammatory bowel disease	DD72	Phase 1	[12]
GSK1482160	DMWDQOV	Pain	MG30-MG3Z	Phase 1	[13]
JNJ-55308942	DM0QZJX	Anhedonia	MB24.2	Phase 1	[3]
JNJ-54175446	DMQ5ZVK	Major depressive disorder	6A70.3	Phase 1	[14]
JNJ-479655	DMDU6GN	Alzheimer disease	8A20	Clinical trial	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2X purinoceptor 3 (P2RX3)	TT2THBD	P2RX3_HUMAN	Inhibitor	[2]
P2X purinoceptor 7 (P2RX7)	TT473XN	P2RX7_HUMAN	Inhibitor	[1]

References

• [1] Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
• [2] Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.
• [3] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
• [7] Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
• [8] Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
• [9] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [11] Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.